Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

Asthma Clinical Trial

Official title:

Phase I/II Study Epinephrine Inhalation Aerosol USP, an HFA-MDI Clinical Study-B for Assessment of Pharmacokinetics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01143051
• Other study ID #: API-E004-CL-B
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 2010
• Est. completion date: June 2010

Study information

• Verified date: September 2018
• Source: Amphastar Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), in healthy male and female adult volunteers. Safety of E004 will also be evaluated, under augmented dose conditions.

Description:

This study is a randomized, evaluator-blind, single dose, three-arm, crossover, PK study, to be conducted in ~18 healthy, male and female, adult volunteers. PK will be studied at two dose strengths (Arm T1 and Arm T2). A currently marketed, non-labeled, Epinephrine CFC-MDI will be used as a Reference Control (Arm C).

• At the Screening Visit and the beginning of each Study Visit, each subject will be trained on the correct self-administration of MDI. The following three randomized treatments will be self-administered, at three Study Visits:

• Treatment T1: Ten (10) inhalations of the low dose E004(125 mcg/inhalation), totaling 1.25 mg of epinephrine;

• Treatment T2: Ten (10) inhalations of the high dose E004 (160 mcg/inhalation), totaling 1.60 mg of epinephrine;

• Treatment C: Ten (10) inhalations of Epinephrine CFC-MDI (220 mcg/inhalation, totaling 2.2 mg of epinephrine base equivalent).

• PK blood samples will be taken from a vein at scheduled time points.

• Safety parameters and adverse drug events, if any, will be monitored and documented at each study visit. An End-of-Study (EOS) safety evaluation will be conducted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Generally healthy, male and female adults, 18-30 yrs of age at Screening;

• Having no clinically significant respiratory, cardiovascular and other systemic or organic illnesses, per investigator discretion;

• Women of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control;

• Having properly consented and satisfied all other inclusion/exclusion criteria as required for this protocol.

• Other criteria apply.

Exclusion Criteria:

• A recent or significant smoking history;

• Use of prohibited drugs or failure to observe the drug washout restrictions;

• Having been on other investigational drug/device studies in the last 30 days prior to Screening.

• Other criteria apply

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• epinephrine inhalation aerosol
Single dose 220 mcg/inhalation, 10 inhalations
• epinephrine inhalation aerosol
HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
• epinephrine inhalation aerosol
HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations

Locations

Country	Name	City	State
United States	Amphastar Location 1	Cypress	California

Sponsors (1)

Lead Sponsor	Collaborator
Amphastar Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Baseline Concentration (C0) of Labeled Epinephrine Total Epinephrine	Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at Baseline (prior to dosing) in each treatment period following a specified washout period (3-14 days), and were analyzed using an established analysis method. Baseline concentration (C0) is the concentration of epinephrine measured in the plasma at this time point.	0 to 30 minutes prior to dosing
Primary	Area Under the Curve From Time Zero to 6 Hours Post-dose (AUC[0-6])	Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Area under the curve from time zero to 6 hours post-dose (AUC[0-6]) was calculated using the trapezoidal rule.	Pre-dose to 6 hours post-dose
Primary	Peak Concentration (Cmax) for Total Epinephrine From Time Zero to 6 Hours Post-dose	Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Peak (maximum) concentration (Cmax) is the highest concentration of epinephrine measured in plasma during the treatment period.	Pre-dose to 6 hours post-dose
Primary	Time to Reach Peak Concentration (Tmax) for Total Epinephrine	Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. tmax is the amount of time it takes for epinephrine to reach peak concentration in plasma during the treatment period.	Pre-dose to 6 hours post-dose
Primary	Half-life (t1/2) for Total Epinephrine	Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Half-life (t1/2) is the amount of time it takes for epinephrine decrease to half the peak concentration in plasma during the treatment period.	Pre-dose to 6 hours post-dose
Primary	Concentration vs. Time for Total Epinephrine From Time Zero to 6 Hours Post-dose	Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method.	Pre-dose to 6 hours post-dose
Secondary	Vital Signs: Systolic Blood Pressure (SBP)	Subject vital signs, i.e., blood pressure and heart rate, were measured prior to study drug dosing (baseline) and up to 360 minutes after dosing during the study visit.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	Vital Signs: Diastolic Blood Pressure (DBP)	Subject vital signs, i.e., blood pressure and heart rate, were measured prior to study drug dosing (baseline) and up to 360 minutes after dosing during the study visit.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	Vital Signs: Heart Rate (HR)	Subject vital signs, i.e., blood pressure and heart rate, were measured prior to study drug dosing (baseline) and up to 360 minutes after dosing during the study visit.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	ECG: QT Interval	Subject QT and QTc Intervals were recorded using a 12-Lead ECG prior to study drug dosing (baseline) and up to 360 minutes after dosing during the study visit.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	ECG: QTc Interval	Subject QT and QTc Intervals were recorded using a 12-Lead ECG prior to study drug dosing (baseline) and up to 360 minutes after dosing during the study visit.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	Serum Glucose Levels	Blood samples used to measure subject serum glucose and potassium levels were collected prior to study drug dosing (baseline) and up to 360 minutes post-dose.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	Serum Potassium Levels	Blood samples used to measure subject serum glucose and potassium levels were collected prior to study drug dosing (baseline) and up to 360 minutes post-dose.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	Hand Tremor Scores	Subjects evaluated hand tremor experiences using a scale from 0 to 3 (0: No tremor; 1: Mild, perceivable; 2: Moderate, observable; and 3: Severe, interfering with hand activities). Hand tremors were evaluated prior to study drug dosing (baseline) and up to 360 minutes post-dose.	Pre-dose (baseline) to 360 minutes post-dose
Secondary	Number of Subjects With Significant Changes in Physical Examination	Physical examinations were performed as a part of Screening and End-of-Study (EOS) procedures. This outcome is a count of the number of subjects that showed a clinically significant change in the EOS physical examination compared to the Screening Visit.	Approximately 6 weeks
Secondary	Number of Subjects With Significant Changes in Laboratory Tests	Laboratory tests (CBC, serum comprehensive metabolic panel, urinalysis, and urinary pregnancy test for women of childbearing potential) were performed as a part of Screening and End-of-Study (EOS) procedures. This outcome is a count of the number of subjects that showed a clinically significant change in the EOS laboratory tests compared to the Screening Visit.	Approximately 6 weeks